Filing Flows › Comparisons › AGIO vs PBYI
Agios Pharmaceuticals vs Puma Biotechnology: AGIO and PBYI compared
Agios Pharmaceuticals is the larger company: $55.4M of revenue in its latest quarter (Q3 2026) against $55.1M for Puma Biotechnology (Q3 2026). Agios Pharmaceuticals is growing faster (+330% against +1% a year earlier). Puma Biotechnology is more profitable, with an operating margin of 9.6% against -139.3%.
Where the money goes: AGIO and PBYI
Agios Pharmaceuticals (AGIO) · Q3 2026
Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart follows the revenue to costs, profit and cash.
Puma Biotechnology (PBYI) · Q3 2026
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart follows the revenue to costs, profit and cash.
| Agios Pharmaceuticals (AGIO) | Puma Biotechnology (PBYI) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $55.4M | $55.1M |
| Revenue growth, Y/Y | +330% | +1% |
| Operating margin | -139.3% | 9.6% |
| Net earnings | −$65.0M | $6.0M |
| Net margin | -117.4% | 10.9% |
| Operating cash flow | −$59.2M | — |
| Market value | $1.9B | — |
| Analysts’ mean target | $45.88 | — |
Where the revenue comes from
Puma Biotechnology
- Product revenue, net: $54.1M (98%)
- Royalty revenue: $1.0M (2%)
Questions
Which is bigger, Agios Pharmaceuticals or Puma Biotechnology?
Agios Pharmaceuticals is the larger company: $55.4M of revenue in its latest quarter (Q3 2026) against $55.1M for Puma Biotechnology (Q3 2026).
Is Agios Pharmaceuticals or Puma Biotechnology growing faster?
Agios Pharmaceuticals is growing faster (+330% against +1% a year earlier).
Which is more profitable, Agios Pharmaceuticals or Puma Biotechnology?
Puma Biotechnology is more profitable, with an operating margin of 9.6% against -139.3%.
More: Agios Pharmaceuticals earnings · how Agios Pharmaceuticals makes money · Puma Biotechnology earnings · how Puma Biotechnology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 8-K filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.